Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +45.19% | -3.21% | -10.61% | +132.98% | -5.94% |
| Gross Profit Growth | +35.75% | -12.68% | -6.65% | +165.84% | -0.86% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.20% | +2.03% | +1.71% | +1.71% | +1.71% |
| Weighted Average Shares Diluted Growth | +2.20% | +2.03% | +1.71% | +1.71% | +1.71% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +218.13% | -173.22% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +217.69% | -172.24% |
| Receivables Growth | +31.62% | -8.76% | -25.78% | +24.89% | +34.78% |
| Inventory Growth | -43.64% | -48.87% | -25.39% | +1.45% | +72.83% |
| Asset Growth | +12.21% | -2.96% | -9.19% | +17.39% | +21.49% |
| Book Value per Share Growth | +14.95% | -39.65% | -41.86% | +66.34% | +59.24% |
| Debt Growth | +323.50% | +143.70% | -1.00% | +1.05% | +3.52% |
| R&D Expense Growth | +10.21% | +2.03% | -14.02% | -23.01% | -2.78% |
| SG&A Expenses Growth | -14.27% | +0.22% | +2.40% | +16.96% | +21.09% |